Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $23
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has maintained a 'Perform' rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $20 to $23.
July 14, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst has maintained a 'Perform' rating on ACADIA Pharmaceuticals and raised the price target from $20 to $23.
The news is directly related to ACADIA Pharmaceuticals. The raised price target indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100